Company intelligence / Profile preview

Aldeyra Therapeutics

Lexington, Massachusetts, United States of Americaaldeyra.com ↗

Ownership: Public · ALDX
Employees: ~9
Development stage: NDA

Overview

Aldeyra's lead product candidate reproxalap received a Complete Response Letter from the FDA in April 2025 for its New Drug Application for Dry Eye Disease. The company has completed enrollment in a new Phase 3 clinical trial with results expected in the second half of 2024, which is designed to enable potential resubmission of the NDA.

Therapeutic areas: GastroenterologyMetabolic DisordersOphthalmologyImmunologyDermatologyRare Diseases
Modalities: Small moleculesRASP modulators
Industry: Biotech

Drug pipeline

10 assets

reproxalap

9 more assets in the full pipeline.

Request access →

Financials

Market cap: $90.5M
Total revenue: $0
Enterprise value: $45.5M

Beyond the preview

Go deeper on Aldeyra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldeyra Therapeutics.

Explore the full profile